Did you know? Elevated CSF protein can be observed in many central nervous system (CNS) disorders. Find out more about the Optilite® Low Level Total Protein assay for urine and CSF total protein analysis: spr.ly/6010xYdyG

Freelite® assays play a pivotal role in accurate diagnosis, treatment monitoring, and disease management to provide a better patient outcome. Read these patient cases which reinforce why Freelite assays have been trusted by the medical community worldwide for over 20 years.

The annual ASH conference is the largest hematology conference in the world, with the 66th ASH conference being the biggest one to date. We are committed to advancing diagnostic technologies to support this vital work. Learn more: spr.ly/6012IVA3Q

Monoclonal gammopathy of undetermined significance (MGUS) may not require treatment. However, it is important to be aware of its potential to progress to malignancies such as Multiple Myeloma or to develop comorbidities like renal insufficiency. spr.ly/6013Ij3jV

In a Swedish multicentric study by Veskovski et al. (2024), experts in haematology highlight the critical impact of serum free light chain analysis methods on myeloma diagnosis. Learn how Freelite ® assays can improve patient outcomes here: spr.ly/6019IcFyU

Monoclonal gammopathy of undetermined significance (MGUS) can lead to complications such as bone fractures or kidney problems. Awareness of the clinical significance of MGUS and regular monitoring of patients is essential for effective patient management: spr.ly/6013IYOYH

Monoclonal gammopathy of undetermined significance (MGUS) is characterised by the presence of abnormal monoclonal protein in the blood. Understanding the clinical implications of MGUS can help in the early identification of potential complications. 👇

We are excited to announce our EXENT® System Clinical Case Study Series. These case studies showcase the use of mass spectrometry in real-world patients. Join us next week for our first case study. #MassSpectrometry #MultipleMyeloma

While MGUS itself might not always cause symptoms, it's important to monitor patients for any changes in health. Regular follow-ups can significantly improve patient outcomes by allowing for the early detection of progression to Myeloma and the development of comorbidities.

In case you missed it! Dr Katie Horton, Medical Science Liaison for EXENT, introduces the first instalment of our case study series. We demonstrate how the EXENT® System, can transform the diagnosis of patients with low-level M-protein spr.ly/60120Ydzs

Trusted in monoclonal gammopathy diagnostics: Over 1,000 labs worldwide, including leading Myeloma centers trust Freelite assays for their free light chain testing. spr.ly/60110FdaF

Introducing Binding Site’s solution for special protein testing. Protein testing benefits from dedicated systems for precise and accurate results. Watch our video to discover how our innovative technologies are transforming the field of protein analysis. spr.ly/60142W1F0

Join us at EuroMedLab 2025 for an exclusive demo of LabLink xL™! See how this dedicated peer-to-peer QC solution for Binding Site controls on the Optilite® Analyser, provides real-time review, precision, and accurate monitoring. Register👉 spr.ly/6019NzyGf #EuroMedLab2025

We're here at EuroMedLab 2025! Excited to kick off the event and explore the latest advancements in protein testing and analysis. Visit our booth to learn more about our innovative solutions and connect with leading experts in the field. #EuroMedLab2025 #ProteinTesting

Patient pathways can be very complex the right diagnostic tools are needed from early diagnosis to monitoring. Optilite® Analyser is designed to meet the growing need for specialized protein testing providing accurate results throughout the patient journey spr.ly/6010NF6L2

Join us at the European Hematology Association Congress in Milan, Italy, June 12-15. Visit us at booth A.05 and speak to our team. #EHA2025

EXENT® System, mass spectrometry solution for M-protein measurement. Learn more about the clinical value of EXENT® System in Multiple Myeloma disease monitoring in patients treated with bispecific antibodies.

The EXENT® System, Mass Spectrometry solution for M-protein measurement. Learn more about use of the EXENT® System in the evaluation of maintenance treatment in Multiple Myeloma patients. #EHA2025

We are at EHA2025, come visit our booth to take the scientific discussions even further. Come talk to us and let's transform Multiple Myeloma assessment. #EHA2025

We are thrilled to announce that Binding Site, a part of Thermo Fisher Scientific, will be featured in seven abstracts at ADLM 2025 in Chicago. Join us to explore groundbreaking research and innovative advancements in protein testing and analysis. spr.ly/60104cvka